IPSEN (IPN.PA) Stock Fundamental Analysis

EPA:IPN • FR0010259150

155.6 EUR
+1.7 (+1.1%)
Last: Feb 17, 2026, 05:35 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Overall IPN gets a fundamental rating of 6 out of 10. We evaluated IPN against 52 industry peers in the Pharmaceuticals industry. IPN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IPN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year IPN was profitable.
  • IPN had a positive operating cash flow in the past year.
  • In the past 5 years IPN has always been profitable.
  • In the past 5 years IPN always reported a positive cash flow from operatings.
IPN.PA Yearly Net Income VS EBIT VS OCF VS FCFIPN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

1.2 Ratios

  • IPN has a better Return On Assets (11.21%) than 78.85% of its industry peers.
  • IPN has a Return On Equity (17.93%) which is in line with its industry peers.
  • The Return On Invested Capital of IPN (21.54%) is better than 86.54% of its industry peers.
Industry RankSector Rank
ROA 11.21%
ROE 17.93%
ROIC 21.54%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IPN.PA Yearly ROA, ROE, ROICIPN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

1.3 Margins

  • IPN has a Profit Margin (13.25%) which is in line with its industry peers.
  • IPN's Profit Margin has declined in the last couple of years.
  • IPN's Operating Margin of 25.32% is in line compared to the rest of the industry. IPN outperforms 59.62% of its industry peers.
  • IPN's Operating Margin has been stable in the last couple of years.
  • IPN has a better Gross Margin (81.66%) than 86.54% of its industry peers.
  • IPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 25.32%
PM (TTM) 13.25%
GM 81.66%
OM growth 3Y-3.38%
OM growth 5Y-1.48%
PM growth 3Y-18.1%
PM growth 5Y-11.16%
GM growth 3Y-0.97%
GM growth 5Y-0.21%
IPN.PA Yearly Profit, Operating, Gross MarginsIPN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IPN is creating value.
  • IPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IPN.PA Yearly Shares OutstandingIPN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPN.PA Yearly Total Debt VS Total AssetsIPN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 4.86 indicates that IPN is not in any danger for bankruptcy at the moment.
  • IPN has a Altman-Z score of 4.86. This is in the better half of the industry: IPN outperforms 73.08% of its industry peers.
  • IPN has a debt to FCF ratio of 1.18. This is a very positive value and a sign of high solvency as it would only need 1.18 years to pay back of all of its debts.
  • IPN's Debt to FCF ratio of 1.18 is amongst the best of the industry. IPN outperforms 90.38% of its industry peers.
  • A Debt/Equity ratio of 0.19 indicates that IPN is not too dependend on debt financing.
  • The Debt to Equity ratio of IPN (0.19) is better than 73.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 1.18
Altman-Z 4.86
ROIC/WACC2.65
WACC8.13%
IPN.PA Yearly LT Debt VS Equity VS FCFIPN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 1.96 indicates that IPN should not have too much problems paying its short term obligations.
  • IPN has a Current ratio of 1.96. This is in the better half of the industry: IPN outperforms 71.15% of its industry peers.
  • IPN has a Quick Ratio of 1.79. This is a normal value and indicates that IPN is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of IPN (1.79) is better than 82.69% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.79
IPN.PA Yearly Current Assets VS Current LiabilitesIPN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 125.29% over the past year.
  • The Earnings Per Share has been decreasing by -4.10% on average over the past years.
  • IPN shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.12%.
  • Measured over the past years, IPN shows a small growth in Revenue. The Revenue has been growing by 7.90% on average per year.
EPS 1Y (TTM)125.29%
EPS 3Y-11.98%
EPS 5Y-4.1%
EPS Q2Q%289.23%
Revenue 1Y (TTM)64.12%
Revenue growth 3Y7.57%
Revenue growth 5Y7.9%
Sales Q2Q%115.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 2.92% on average over the next years.
  • IPN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.69% yearly.
EPS Next Y0.62%
EPS Next 2Y2.1%
EPS Next 3Y4.86%
EPS Next 5Y2.92%
Revenue Next Year3.73%
Revenue Next 2Y4.64%
Revenue Next 3Y5.11%
Revenue Next 5Y2.69%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
IPN.PA Yearly Revenue VS EstimatesIPN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
IPN.PA Yearly EPS VS EstimatesIPN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 16.70, which indicates a correct valuation of IPN.
  • Based on the Price/Earnings ratio, IPN is valued a bit cheaper than 69.23% of the companies in the same industry.
  • IPN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
  • IPN is valuated correctly with a Price/Forward Earnings ratio of 13.64.
  • Based on the Price/Forward Earnings ratio, IPN is valued a bit cheaper than 76.92% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. IPN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 16.7
Fwd PE 13.64
IPN.PA Price Earnings VS Forward Price EarningsIPN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IPN is valued cheaply inside the industry as 96.15% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IPN indicates a somewhat cheap valuation: IPN is cheaper than 75.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.75
EV/EBITDA 5.84
IPN.PA Per share dataIPN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of IPN may justify a higher PE ratio.
PEG (NY)26.8
PEG (5Y)N/A
EPS Next 2Y2.1%
EPS Next 3Y4.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.95%, IPN is not a good candidate for dividend investing.
  • IPN's Dividend Yield is comparable with the industry average which is at 1.91.
  • With a Dividend Yield of 0.95, IPN pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.95%

5.2 History

  • The dividend of IPN has a limited annual growth rate of 3.72%.
Dividend Growth(5Y)3.72%
Div Incr Years1
Div Non Decr Years4
IPN.PA Yearly Dividends per shareIPN.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 14.95% of the earnings are spent on dividend by IPN. This is a low number and sustainable payout ratio.
  • IPN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP14.95%
EPS Next 2Y2.1%
EPS Next 3Y4.86%
IPN.PA Yearly Income VS Free CF VS DividendIPN.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M
IPN.PA Dividend Payout.IPN.PA Dividend Payout, showing the Payout Ratio.IPN.PA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IPSEN

EPA:IPN (2/17/2026, 5:35:15 PM)

155.6

+1.7 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)07-29
Inst Owners15.35%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap13.04B
Revenue(TTM)5.87B
Net Income(TTM)777.50M
Analysts69.47
Price Target135.82 (-12.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.95%
Yearly Dividend1.2
Dividend Growth(5Y)3.72%
DP14.95%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.97%
PT rev (3m)3.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.8%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.25%
Valuation
Industry RankSector Rank
PE 16.7
Fwd PE 13.64
P/S 2.22
P/FCF 15.75
P/OCF 11.28
P/B 3.01
P/tB 9.22
EV/EBITDA 5.84
EPS(TTM)9.32
EY5.99%
EPS(NY)11.41
Fwd EY7.33%
FCF(TTM)9.88
FCFY6.35%
OCF(TTM)13.8
OCFY8.87%
SpS70
BVpS51.74
TBVpS16.87
PEG (NY)26.8
PEG (5Y)N/A
Graham Number104.16
Profitability
Industry RankSector Rank
ROA 11.21%
ROE 17.93%
ROCE 27.02%
ROIC 21.54%
ROICexc 29.88%
ROICexgc 113.42%
OM 25.32%
PM (TTM) 13.25%
GM 81.66%
FCFM 14.11%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-3.38%
OM growth 5Y-1.48%
PM growth 3Y-18.1%
PM growth 5Y-11.16%
GM growth 3Y-0.97%
GM growth 5Y-0.21%
F-Score7
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 1.18
Debt/EBITDA 0.4
Cap/Depr 52.58%
Cap/Sales 5.6%
Interest Coverage 250
Cash Conversion 54.79%
Profit Quality 106.48%
Current Ratio 1.96
Quick Ratio 1.79
Altman-Z 4.86
F-Score7
WACC8.13%
ROIC/WACC2.65
Cap/Depr(3y)123.84%
Cap/Depr(5y)123.25%
Cap/Sales(3y)11.93%
Cap/Sales(5y)11.8%
Profit Quality(3y)111.08%
Profit Quality(5y)104.31%
High Growth Momentum
Growth
EPS 1Y (TTM)125.29%
EPS 3Y-11.98%
EPS 5Y-4.1%
EPS Q2Q%289.23%
EPS Next Y0.62%
EPS Next 2Y2.1%
EPS Next 3Y4.86%
EPS Next 5Y2.92%
Revenue 1Y (TTM)64.12%
Revenue growth 3Y7.57%
Revenue growth 5Y7.9%
Sales Q2Q%115.57%
Revenue Next Year3.73%
Revenue Next 2Y4.64%
Revenue Next 3Y5.11%
Revenue Next 5Y2.69%
EBIT growth 1Y87.65%
EBIT growth 3Y3.94%
EBIT growth 5Y6.31%
EBIT Next Year24.19%
EBIT Next 3Y10.15%
EBIT Next 5Y4.57%
FCF growth 1Y522.48%
FCF growth 3Y4.75%
FCF growth 5Y5.6%
OCF growth 1Y26.34%
OCF growth 3Y5.92%
OCF growth 5Y8.44%

IPSEN / IPN.PA FAQ

What is the fundamental rating for IPN stock?

ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA.


What is the valuation status of IPSEN (IPN.PA) stock?

ChartMill assigns a valuation rating of 5 / 10 to IPSEN (IPN.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for IPSEN?

IPSEN (IPN.PA) has a profitability rating of 6 / 10.


What is the financial health of IPSEN (IPN.PA) stock?

The financial health rating of IPSEN (IPN.PA) is 7 / 10.


How sustainable is the dividend of IPSEN (IPN.PA) stock?

The dividend rating of IPSEN (IPN.PA) is 3 / 10 and the dividend payout ratio is 14.95%.